{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:25:26Z","timestamp":1790270726748,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Maintenance therapy using poly(adenosine diphosphate-ribose)polymerase inhibitors may have adverse events, including hematological toxicity, and may limit therapeutic potential in patients with cancer. Niraparib-induced anemia negatively impacts one\u2019s quality of life. Its amelioration by ferrous iron (for example, sodium ferrous citrate), folic acid, or vitamin B12 has not been supported. Oral ferric citrate hydrate increases circulating levels of iron and hepatic iron accumulation, improving renal anemia in patients with kidney failure receiving hemodialysis. The uptake of ferric iron is considered to be much higher than that of ferrous iron.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>The admitted patient was a 57-year-old Japanese woman with stage IIIB ovarian cancer who underwent primary debulking surgery and standard carboplatin\u2013paclitaxel chemotherapy combined with bevacizumab, followed by niraparib (200\u00a0mg\/day) maintenance therapy. The patient started oral SFC (100\u00a0mg\/day) to treat niraparib-related anemia. However, she required two units of packed red blood cell transfusions three times within 3\u00a0months after starting niraparib treatment. The patient was diagnosed with niraparib-related anemia. The blood test results after 1\u00a0month from the start of niraparib treatment were as follows: red blood cells, 211\u2009\u00d7\u200910<jats:sup>4<\/jats:sup>\/\u03bcL; hemoglobin, 7.0\u00a0g\/dL; hematocrit, 20.8%; reticulocyte, 0.2%; platelet count, 18.0\u2009\u00d7\u200910<jats:sup>4<\/jats:sup>\/\u03bcL. She was switched to oral ferric citrate hydrate with a dose of 500\u00a0mg per day and resumed niraparib treatment. She did not experience grade 3 niraparib-related hematological toxicity and achieved blood transfusion independence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Ferric citrate hydrate may be a safe, effective, and well-tolerated oral drug for treating patients with niraparib-related anemia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-022-03666-3","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:02:50Z","timestamp":1669338170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of oral ferric citrate hydrate treatment for anemia caused by niraparib: a case report"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8124-6269","authenticated-orcid":false,"given":"Hiroshi","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"3666_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, et\u00a0al. Cancer Statistics 2021. CA Cancer J Clin. 2021;71:7\u201333. https:\/\/doi.org\/10.3322\/caac.21654.","journal-title":"CA Cancer J Clin"},{"key":"3666_CR2","first-page":"CD005343","volume":"2019","author":"SL Coleridge","year":"2019","unstructured":"Coleridge SL, Bryant A, Lyons TJ, et\u00a0al. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2019;2019:CD005343.","journal-title":"Cochrane Database Syst Rev"},{"key":"3666_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, PRIMA\/ENGOT-OV26\/GOG-3012 Investigators, et\u00a0al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391\u2013402. https:\/\/doi.org\/10.1056\/NEJMoa1910962.","journal-title":"N Engl J Med"},{"key":"3666_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.maturitas.2015.01.015","volume":"81","author":"S Tangutoori","year":"2015","unstructured":"Tangutoori S, Baldwin P, Sridhar S. PARP inhibitors: a new era of targeted therapy. Maturitas. 2015;81:5\u20139. https:\/\/doi.org\/10.1016\/j.maturitas.2015.01.015.","journal-title":"Maturitas"},{"key":"3666_CR5","doi-asserted-by":"publisher","first-page":"S613","DOI":"10.1016\/j.annonc.2020.08.950","volume":"31","author":"S Banerjee","year":"2020","unstructured":"Banerjee S, Moore KN, Colombo N, et\u00a0al. Maintenance olaparib for patients (Pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (Y) follow-up (F\/U) from SOLO1. Ann Oncol. 2020;31:S613. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.950.","journal-title":"Ann Oncol"},{"key":"3666_CR6","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA, et\u00a0al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22:620\u201331. https:\/\/doi.org\/10.1016\/S1470-2045(21)00073-5.","journal-title":"Lancet Oncol"},{"key":"3666_CR7","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore KN, Secord AA, Geller MA, et\u00a0al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:636\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(19)30029-4.","journal-title":"Lancet Oncol"},{"key":"3666_CR8","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1177\/1078155218800156","volume":"25","author":"NS Patibandla","year":"2019","unstructured":"Patibandla NS, Monga DK. Niraparib\u2014a promising drug with hematological toxicity. J Oncol Pharm Pract. 2019;25:1749\u201353. https:\/\/doi.org\/10.1177\/1078155218800156.","journal-title":"J Oncol Pharm Pract"},{"key":"3666_CR9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.21037\/atm-21-2252","volume":"9","author":"J Wang","year":"2021","unstructured":"Wang J, Zhu J. Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib. Ann Transl Med. 2021;9:869. https:\/\/doi.org\/10.21037\/atm-21-2252.","journal-title":"Ann Transl Med"},{"key":"3666_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/curroncol29010029","volume":"29","author":"A Pagkali","year":"2022","unstructured":"Pagkali A, Mamais I, Michalinos A, et\u00a0al. Safety profile of niraparib as maintenance therapy for ovarian cancer: a systematic review and meta-analysis. Curr Oncol. 2022;29:321\u201336. https:\/\/doi.org\/10.3390\/curroncol29010029.","journal-title":"Curr Oncol"},{"issue":"8","key":"3666_CR11","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1634\/theoncologist.2015-0268","volume":"21","author":"KN Moore","year":"2016","unstructured":"Moore KN, Monk BJ. Patient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancer. Oncologist. 2016;21(8):954\u201363. https:\/\/doi.org\/10.1634\/theoncologist.2015-0268.","journal-title":"Oncologist"},{"issue":"7","key":"3666_CR12","first-page":"339","volume":"32","author":"RE O'Cearbhaill","year":"2018","unstructured":"O\u2019Cearbhaill RE. Using PARP inhibitors in advanced ovarian cancer. Oncology (Williston Park). 2018;32(7):339\u201343.","journal-title":"Oncology (Williston Park)"},{"key":"3666_CR13","doi-asserted-by":"publisher","first-page":"c25","DOI":"10.1159\/000341922","volume":"121","author":"M Sinsakul","year":"2012","unstructured":"Sinsakul M, Sika M, Koury M, Shapiro W, Collaborative Study Group, et\u00a0al. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract. 2012;121:c25\u20139.","journal-title":"Nephron Clin Pract"},{"key":"3666_CR14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/ki.1996.334","volume":"50","author":"HT Sponsel","year":"1996","unstructured":"Sponsel HT, Alfrey AC, Hammond WS, et\u00a0al. Effect of iron on renal tubular epithelial cells. Kidney Int. 1996;50:436\u201344. https:\/\/doi.org\/10.1038\/ki.1996.334.","journal-title":"Kidney Int"},{"key":"3666_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12185-021-03123-9","volume":"114","author":"N Komatsu","year":"2021","unstructured":"Komatsu N, Arita K, Mitsui H, et\u00a0al. Efficacy and safety of ferric citrate hydrate compared with sodium ferrous citrate in Japanese patients with iron deficiency anemia: a randomized, double-blind, phase 3 non-inferiority study. Int J Hematol. 2021;114:8\u201317. https:\/\/doi.org\/10.1007\/s12185-021-03123-9.","journal-title":"Int J Hematol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03666-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-022-03666-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03666-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:02:52Z","timestamp":1669338172000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-022-03666-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3666"],"URL":"https:\/\/doi.org\/10.1186\/s13256-022-03666-3","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,25]]},"assertion":[{"value":"18 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript is a case report using patient\u2019s laboratory data in clinical practice. Therefore, we believe that this manuscript does not require the approval of the Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"440"}}